Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties
Top Cited Papers
- 25 March 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 1 (6) , 435-449
- https://doi.org/10.1021/cn100008c
Abstract
The interplay among commonly used physicochemical properties in drug design was examined and utilized to create a prospective design tool focused on the alignment of key druglike attributes. Using a set of six physicochemical parameters ((a) lipophilicity, calculated partition coefficient (ClogP); (b) calculated distribution coefficient at pH = 7.4 (ClogD); (c) molecular weight (MW); (d) topological polar surface area (TPSA); (e) number of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compounds (N = 11 303). The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0−6), in comparison to 60% of the Pfizer CNS candidates. This analysis suggests that this algorithm could potentially be used to identify compounds with a higher probability of successfully testing hypotheses in the clinic. In addition, a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set. The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure−activity relationships (SAR) by expanding medicinal chemistry design space through a holistic assessment approach. Based on six physicochemical properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compounds with increased probability of success.Keywords
This publication has 20 references indexed in Scilit:
- Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety AttributesACS Chemical Neuroscience, 2010
- Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction ApproachesThe Journal of Clinical Pharmacology, 2009
- The influence of lead discovery strategies on the properties of drug candidatesNature Reviews Drug Discovery, 2009
- Physiochemical drug properties associated with in vivo toxicological outcomesBioorganic & Medicinal Chemistry Letters, 2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Identifying Promising Compounds in Drug Discovery: Genetic Algorithms and Some New Statistical TechniquesJournal of Chemical Information and Modeling, 2007
- Early evaluation of compound QT prolongation effects: A predictive 384-well fluorescence polarization binding assay for measuring hERG blockadeJournal of Pharmacological and Toxicological Methods, 2006
- Research perspectives for pre-screening alternatives to animal experimentationOn the relevance of cytotoxicity measurements, barrier passage determinations and high throughput screening in vitro to select potentially hazardous compounds in large sets of chemicalsToxicology and Applied Pharmacology, 2005
- Lead- and drug-like compounds: the rule-of-five revolutionDrug Discovery Today: Technologies, 2004
- The impact of drug-induced QT interval prolongation on drug discovery and developmentNature Reviews Drug Discovery, 2003